Here, we uncovered distinct crosstalk mechanisms that shape the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL, thereby revealing new potential therapeutic targets. The gene discussed is BCL2L1; the disease is B-cell chronic lymphocytic leukemia.